Safety and Efficacy of Cannabis in Tourette Syndrome

Tourette Syndrome Clinical Trial

Official title:

A Double-blind, Randomized, Placebo-controlled Crossover Pilot Trial of Medical Cannabis in Adults With Tourette Syndrome

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03247244
• Other study ID #: 14-7726
• Status: Terminated
• Phase: Phase 2
• Start date: January 15, 2018
• Est. completion date: January 27, 2020

Study information

• Verified date: January 2021
• Source: University Health Network, Toronto
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

For many individuals with Tourette syndrome (TS), available medications do not help with their symptoms, or cause significant side effects. Two small controlled trials have investigated the effect of oral delta-9-tetrahydrocannabinol (THC), a principal psychoactive ingredient of cannabis, in TS patients. While these trials have shown promising results, the effect sizes were not as large and consistent as those reported by patients with regards to inhaled cannabis (smoked or vaporized). Indeed, based on anecdotal evidence, patients have much greater improvement in their symptoms using inhaled cannabis than using cannabinoid pharmaceuticals. However, there have been no controlled trials of inhaled medical cannabis for TS to date. Furthermore, various medical cannabis products are authorized in Canada with different contents of THC and cannabidiol (CBD), another primary cannabinoid. No data exists regarding the dosing, efficacy and safety of these products in the treatment of TS. To gather such data, a double-blind, randomized, crossover pilot trial will be conducted to compare the efficacy and safety of three vaporized medical cannabis products with different THC and CBD contents, as well as placebo, in adults with TS. As well, the PK/PD profile of THC and CBD of the products will be assessed and correlated with tic symptoms

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 15
• Est. completion date: January 27, 2020
• Est. primary completion date: June 6, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Male or female adult, 18-65 years of age (inclusive) at the time of signing the informed consent.

• The subject meets current DSM-5 diagnostic criteria for TS[6], diagnosed by a neuropsychiatrist with expertise in TS and related conditions.

• YGTSS-TTS =16, frequency subscore = 5 and intensity subscore = 2. In addition, tic free intervals do not last more than two minutes based on both self-reporting and observation by clinician at both screening and Week 0 (randomization). This requirement is for the purpose of minimizing the potential for floor effects given the relatively short window for assessing effect on symptoms in this single-dose trial.

• The subject is able and willing to refrain from using any non-study cannabis during the screening and treatment phases of the study.

• Females of childbearing potential (defined by menarche and not having undergone surgical sterilization/hysterectomy) must have a negative pregnancy test, must be practicing acceptable double-barrier methods of contraception (or can confirm abstinence at each scheduled visit), and must not be breast feeding.

• Written informed consent must be obtained from the subject prior to the initiation of any protocol-required procedures.

• The subject is able to comprehend and satisfactorily comply with the protocol requirements.

Exclusion Criteria:

• • The subject and/or his/her family have a history of psychosis, schizophrenia or bipolar disorder.

• Sexually active females of childbearing potential who will not commit to utilizing 2 of the approved birth control methods or who will not remain abstinent during the trial; Females who are breast-feeding and/or who have a positive serum pregnancy test result prior at the time of screening.

• The subject represents a significant risk of committing suicide (current suicide plan or attempt in past 2 years) or committing homicide.

• The subject has a history of serious head injury, seizure disorder, or developmental delay (intelligence quotient=85).

• The subject has either of: cardiovascular disease; respiratory disease such as chronic obstructive pulmonary disease (COPD) or lung cancer (asthma is not an exclusionary criterion); hepatitis.

• The subject has a current or past history of substance abuse within the last 5 years, with the exception of cannabis.

• The subject is using cannabis regularly for the treatment of TS.

• The subject has any abnormal laboratory tests and vital sign results which in the investigator's judgment is medically significant and would impact the safety of the subject or the interpretation of the study results.

Related Conditions & MeSH terms

• Marijuana Abuse
• Syndrome
• Tourette Syndrome

Intervention

Drug:
• Cannabis
THC 10%, CBD <0.5%
• Cannabis
THC 8.6%, CBD 8.6%
• Cannabis
THC 0.6%, CBD 14%

Locations

Country	Name	City	State
Canada	Toronto Western Hospital - Tourette Syndrome Neurodevelopmental Clinic	Toronto	Ontario

Sponsors (1)

Lead Sponsor	Collaborator
University Health Network, Toronto

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Area under the plasma concentration versus time curve of CBD and 11-OH-THC	Determine a temporal relationship between changes in THC/CBD plasma concentrations and tic severity	6 hours
Other	Premonitory Urge for Tics Scale (PUTS)	Assesses the intensity of premonitory urges	1 hour
Other	Clinical Global Impression- Improvement Scale (CGI-I)	Assesses how improved symptoms are after an intervention	1 hour
Primary	Modified Rush Video-Based Tic Rating Scale	Can be used to assess changes in frequency and severity of tics	10 minutes
Secondary	The Marijuana Effect Expectancy Questionnaire (MEEQ)	To assess tolerability of cannabis products	6 hours